login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ZEVRA THERAPEUTICS INC (ZVRA) Stock News
USA
-
Nasdaq
- NASDAQ:ZVRA -
US4884452065
-
Common Stock
8.71
USD
+0.05 (+0.58%)
Last: 12/5/2025, 8:00:02 PM
8.71
USD
0 (0%)
After Hours:
12/5/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ZVRA Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Zevra Therapeutics
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
17 days ago - By: Zevra Therapeutics
Zevra Therapeutics, Inc. Announces CFO Transition
a month ago - By: The Motley Fool
Zevra (ZVRA) Q3 2025 Earnings Call Transcript
a month ago - By: Zacks Investment Research
- Mentions:
AKBA
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
a month ago - By: Zevra Therapeutics
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
a month ago - By: Benzinga
- Mentions:
TECH
INSE
GEF
SKYT
...
Earnings Scheduled For November 5, 2025
4 months ago - By: Benzinga
A Look at Zevra Therapeutics's Upcoming Earnings Report
a month ago - By: Zevra Therapeutics
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
a month ago - By: Zevra Therapeutics
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
2 months ago - By: Zevra Therapeutics
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Zevra Therapeutics
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium
3 months ago - By: Zevra Therapeutics
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
3 months ago - By: Zevra Therapeutics
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
3 months ago - By: Zevra Therapeutics
Zevra Therapeutics to Participate at Upcoming Investor Conferences in September
4 months ago - By: Zacks Investment Research
- Mentions:
PROF
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)
4 months ago - By: Investor's Business Daily
- Mentions:
AMGN
Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.
4 months ago - By: The Motley Fool
Zevra Revenue Jumps 486 Percent in Q2
4 months ago - By: Zacks Investment Research
- Mentions:
PROF
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
4 months ago - By: Zevra Therapeutics
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update
4 months ago - By: Zacks Investment Research
- Mentions:
GILD
INO
DERM
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
4 months ago - By: Zacks Investment Research
What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing'
4 months ago - By: Zevra Therapeutics
Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
4 months ago - By: Zacks Investment Research
- Mentions:
COLL
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
4 months ago - By: Zevra Therapeutics
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
4 months ago - By: Zevra Therapeutics
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
5 months ago - By: Zevra Therapeutics
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
Please enable JavaScript to continue using this application.